Cannabis and Autoimmunity: Possible Mechanisms of Action

References

• Bonini SA, Premoli M, Tambaro S, et al. Cannabis sativa: a comprehensive ethnopharmacological review of a medicinal plant with a long history. J Ethnopharmacol. 2018;227:300–315. doi:10.1016/j.jep.2018.09.004
   PubMed Web of Science ®Google Scholar
• Touw M. The religious and medicinal uses of cannabis in China, India and Tibet. J Psychoactive Drugs. 1981;13:23–34. doi:10.1080/02791072.1981.10471447
   PubMed Web of Science ®Google Scholar
• Chopra IC, Chopra RN. The use of the cannabis drugs in India. Bull Narc. 1957;9:4–29.
   Google Scholar
• Hall W. The Indian Hemp Drugs Commission 1893-1894. Addiction. 2019;114(9):1679–1682.
   Google Scholar
• Hanuš LO, Meyer SM, Muñoz E, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33:1357–1392. doi:10.1039/C6NP00074F
   PubMed Web of Science ®Google Scholar
• Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of Hashish. J Am Chem Soc. 1964;86:1646–1647. doi:10.1021/ja01062a046
   Web of Science ®Google Scholar
• Russell C, Rueda S, Room R, Tyndall M, Fischer B. Routes of administration for cannabis use - basic prevalence and related health outcomes: a scoping review and synthesis. Int J Drug Policy. 2018;52:87–96. doi:10.1016/j.drugpo.2017.11.008
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol. 1998;359:1–18. doi:10.1016/S0014-2999(98)00649-9
   PubMed Web of Science ®Google Scholar
• Cabral GA, Rogers TJ, Lichtman AH. Turning over a new leaf: cannabinoid and endocannabinoid modulation of immune function. J Neuroimmune Pharmacol. 2015;10:193–203. doi:10.1007/s11481-015-9615-z
   Web of Science ®Google Scholar
• Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147:S163–S171. doi:10.1038/sj.bjp.0706406
   PubMed Web of Science ®Google Scholar
• Zgair A, Lee JB, Wong JCM, et al. Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Sci Rep. 2017;7:1–12. doi:10.1038/s41598-017-15026-z
   Web of Science ®Google Scholar
• Gould J. 4 Big questions. Nature. 2015;527:4. doi:10.1038/nj7577-265a
   Web of Science ®Google Scholar
• Wang T, Collet J-P, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178:1669–1678. doi:10.1503/cmaj.071178
   PubMed Web of Science ®Google Scholar
• Fitzcharles MA, Baerwald C, Ablin J, Häuser W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. Schmerz. 2016;30:47–61. doi:10.1007/s00482-015-0084-3
   PubMed Web of Science ®Google Scholar
• Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a Systematic Review and Meta- Analysis of Randomized Controlled Trials. Pain Physician. 2017;6:E755–E796. doi:10.36076/ppj.20.5.E755
   Google Scholar
• Maccallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–19. doi:10.1016/j.ejim.2018.01.004
   PubMed Web of Science ®Google Scholar
• Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152:1092–1101. doi:10.1038/sj.bjp.0707460
   PubMed Web of Science ®Google Scholar
• Almogi-Hazan O, Or R. Cannabis, the endocannabinoid system and immunity—the journey from the bedside to the bench and back. Int J Mol Sci. 2020;21:1–17. doi:10.3390/ijms21124448
   Web of Science ®Google Scholar
• Capasso R, Borrelli F, Aviello G, et al. Cannabidiol, extracted from cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol. 2008;154:1001–1008. doi:10.1038/bjp.2008.177
   PubMed Web of Science ®Google Scholar
• Massi P, Valenti M, Vaccani A, et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem. 2008;104:1091–1100. doi:10.1111/j.1471-4159.2007.05073.x
   PubMed Web of Science ®Google Scholar
• Oláh A, Szekanecz Z, Bíró T. Targeting cannabinoid signaling in the immune system: “High”-ly exciting questions, possibilities, and challenges. Front Immunol. 2017;8:1. doi:10.3389/fimmu.2017.01487
   Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–1949. doi:10.1126/science.1470919
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215:89–97.
   PubMed Web of Science ®Google Scholar
• Laezza C, Pagano C, Navarra G, et al. The endocannabinoid system: a target for cancer treatment. Int J Mol Sci. 2020;21. doi:10.3390/ijms21030747
   Web of Science ®Google Scholar
• Perisetti A, Rimu AH, Khan SA, Bansal P, Goyal H. Role of cannabis in inflammatory bowel diseases. Ann Gastroenterol. 2020;33:134–144. doi:10.20524/aog.2020.0452
   PubMed Web of Science ®Google Scholar
• Di Marzo V, De Petrocellis L. Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc B Biol Sci. 2012;367:3216–3228.
   PubMed Web of Science ®Google Scholar
• Jourdan T, Djaouti L, Demizieux L, Gresti J, Vergès B, Degrace P. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes. 2010;59:926–934. doi:10.2337/db09-1482
   PubMed Web of Science ®Google Scholar
• Busquets Garcia A, Soria-Gomez E, Bellocchio L, Marsicano G. Cannabinoid receptor type-1: breaking the dogmas. F1000Research. 2016;5:1–9. doi:10.12688/f1000research.8245.1
   Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61–65. doi:10.1038/365061a0
   PubMed Web of Science ®Google Scholar
• Kinsey SG, Mahadevan A, Zhao B, et al. The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology. 2011;60:244–251. doi:10.1016/j.neuropharm.2010.09.004
   PubMed Web of Science ®Google Scholar
• Núñez E, Benito C, Pazos MR, et al. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse. 2004;53:208–213.
   PubMed Web of Science ®Google Scholar
• Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232:54–61. doi:10.1111/j.1432-1033.1995.tb20780.x
   PubMedGoogle Scholar
• Parolaro D. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci. 1999;65:637–644. doi:10.1016/S0024-3205(99)00286-6
   PubMed Web of Science ®Google Scholar
• Kaplan BLF, Springs AEB, Kaminski NE. The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem Pharmacol. 2008;76:726–737. doi:10.1016/j.bcp.2008.06.022
   PubMed Web of Science ®Google Scholar
• Ligresti A, De Petrocellis L, Di Marzo V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev. 2016;96:1593–1659. doi:10.1152/physrev.00002.2016
   PubMed Web of Science ®Google Scholar
• Sharma CV, Long JH, Shah S, et al. First evidence of the conversion of paracetamol to AM404 in human cerebrospinal fluid. J Pain Res. 2017;10:2703–2709. doi:10.2147/JPR.S143500
   PubMed Web of Science ®Google Scholar
• Pertwee RG. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9-tetrahydrocannabinol, cannabidiol and Δ 9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199–215. doi:10.1038/sj.bjp.0707442
   PubMed Web of Science ®Google Scholar
• Pisanti S, Malfitano AM, Ciaglia E, et al. Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017;175:133–150. doi:10.1016/j.pharmthera.2017.02.041
   PubMed Web of Science ®Google Scholar
• Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172:4790–4805. doi:10.1111/bph.13250
   PubMed Web of Science ®Google Scholar
• Morgan CJA, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry. 2010;197:285–290. doi:10.1192/bjp.bp.110.077503
   PubMed Web of Science ®Google Scholar
• Woelfl T, Rohleder C, Mueller JK, et al. Effects of cannabidiol and delta-9-tetrahydrocannabinol on emotion, cognition, and attention: a Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers. Front Psychiatry. 2020;11. doi:10.3389/fpsyt.2020.576877
   Web of Science ®Google Scholar
• Russo EB, Marcu J. Cannabis pharmacology: the usual suspects and a few promising leads. Adv Pharmacol. 2017;80:67–134.
   PubMedGoogle Scholar
• Gonçalves ECD, Baldasso GM, Bicca MA, Paes RS, Capasso R, Dutra RC. Terpenoids, cannabimimetic ligands, beyond the cannabis plant. Molecules. 2020;25:1567. doi:10.3390/molecules25071567
   Web of Science ®Google Scholar
• Mammana S, Cavalli E, Gugliandolo A, et al. Could the combination of two non-psychotropic cannabinoids counteract neuroinflammation? Effectiveness of cannabidiol associated with cannabigerol. Med. 2019;55. doi:10.3390/medicina55110747
   Web of Science ®Google Scholar
• Udoh M, Santiago M, Devenish S, McGregor IS, Connor M. Cannabichromene is a cannabinoid CB2 receptor agonist. Br J Pharmacol. 2019;176:4537–4547. doi:10.1111/bph.14815
   Web of Science ®Google Scholar
• Bento AF, Marcon R, Dutra RC, et al. β-caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway. Am J Pathol. 2011;178:1153–1166. doi:10.1016/j.ajpath.2010.11.052
   PubMed Web of Science ®Google Scholar
• de Almeida AAC, Silva RO, Nicolau LAD, et al. Physio-pharmacological investigations about the anti-inflammatory and antinociceptive efficacy of (+)-limonene epoxide. Inflammation. 2017;40:511–522. doi:10.1007/s10753-016-0496-y
   PubMed Web of Science ®Google Scholar
• Ramalho TR, Filgueiras LR, De Oliveira MTP, et al. Gamma-Terpinene modulation of LPS-stimulated macrophages is dependent on the PGE2/IL-10 Axis. Planta Med. 2016;82:1341–1345. doi:10.1055/s-0042-107799
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74:129–180. doi:10.1016/S0163-7258(97)82001-3
   PubMed Web of Science ®Google Scholar
• Vaughan CW, Christie MJ. Retrograde signalling by endocannabinoids. Handb Exp Pharmacol. 2005;(168):367–83. doi:10.1007/3-540-26573-2_12
   Google Scholar
• Pisanu A, Acquas E, Fenu S, Di Chiara G. Modulation of Δ9-THC-induced increase of cortical and hippocampal acetylcholine release by μ opioid and D1 dopamine receptors. Neuropharmacology. 2006;50:661–670. doi:10.1016/j.neuropharm.2005.11.023
   Web of Science ®Google Scholar
• Pistis M, Ferraro L, Pira L, et al. Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res. 2002;948:155–158. doi:10.1016/S0006-8993(02)03055-X
   PubMed Web of Science ®Google Scholar
• Vrechi TA, Crunfli F, Costa AP, Torrão AS. Cannabinoid receptor Type 1 agonist ACEA protects neurons from death and attenuates endoplasmic reticulum stress-related apoptotic pathway signaling. Neurotox Res. 2018;33:846–855. doi:10.1007/s12640-017-9839-1
   Web of Science ®Google Scholar
• Xu C, Hermes DJ, Nwanguma B, et al. Endocannabinoids exert CB1 receptor-mediated neuroprotective effects in models of neuronal damage induced by HIV-1 Tat protein. Mol Cell Neurosci. 2017;83:92–102. doi:10.1016/j.mcn.2017.07.003
   Web of Science ®Google Scholar
• Saliba SW, Marcotegui AR, Fortwängler E, et al. Correction: AM404, paracetamol metabolite, prevents prostaglandin synthesis in activated microglia by inhibiting COX activity. J Neuroinflammation. 2018;15:34. doi:10.1186/s12974-018-1072-1
   Web of Science ®Google Scholar
• Lowin T, Apitz M, Anders S, Straub RH. Anti-inflammatory effects of N-acylethanolamines in rheumatoid arthritis synovial cells are mediated by TRPV1 and TRPA1 in a COX-2 dependent manner. Arthritis Res Ther. 2015;17. doi:10.1186/s13075-015-0845-5
   Web of Science ®Google Scholar
• Watzl B, Scuderi P, Watson RR. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol. 1991;13:1091–1097. doi:10.1016/0192-0561(91)90160-9
   PubMed Web of Science ®Google Scholar
• Watzl B, Scuderi P, Watson RR. Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. Adv Exp Med Biol. 1991:63–70.
   Google Scholar
• Nichols JM, Kaplan BLF. Immune responses regulated by cannabidiol. Cannabis Cannabinoid Res. 2020;5:12–31. doi:10.1089/can.2018.0073
   PubMedGoogle Scholar
• Wu HY, Chang AC, Wang CC, et al. Cannabidiol induced a contrasting pro-apoptotic effect between freshly isolated and precultured human monocytes. Toxicol Appl Pharmacol. 2010;246:141–147. doi:10.1016/j.taap.2010.05.003
   Web of Science ®Google Scholar
• Jenny M, Santer E, Pirich E, Schennach H, Fuchs D. Δ9-Tetrahydrocannabinol and cannabidiol modulate mitogen-induced tryptophan degradation and neopterin formation in peripheral blood mononuclear cells in vitro. J Neuroimmunol. 2009;207:75–82. doi:10.1016/j.jneuroim.2008.12.004
   Web of Science ®Google Scholar
• Kozela E, Lev N, Kaushansky N, et al. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol. 2011;163:1507–1519. doi:10.1111/j.1476-5381.2011.01379.x
   PubMed Web of Science ®Google Scholar
• Jan TR, Kaminski NE. Role of mitogen-activated protein kinases in the differential regulation of interleukin-2 by cannabinol. J Leukoc Biol. 2001;69:841–849.
   Web of Science ®Google Scholar
• Chen W, Kaplan BLF, Pike ST, et al. Magnitude of stimulation dictates the cannabinoid-mediated differential T cell response to HIV gp120. J Leukoc Biol. 2012;92:1093–1102. doi:10.1189/jlb.0212082
   Web of Science ®Google Scholar
• Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204–e1211. doi:10.1212/WNL.0000000000005254
   PubMed Web of Science ®Google Scholar
• Elliott DM, Singh N, Nagarkatti M, Nagarkatti PS. Cannabidiol attenuates experimental autoimmune encephalomyelitis model of multiple sclerosis through induction of myeloid-derived suppressor cells. Front Immunol. 2018;9. doi:10.3389/fimmu.2018.01782
   Web of Science ®Google Scholar
• Selvi E, Lorenzini S, Garcia-Gonzalez E, et al. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin Exp Rheumatol. 2008;26:574–581.
   PubMed Web of Science ®Google Scholar
• Kinsey SG, Naidu PS, Cravatt BF, Dudley DT, Lichtman AH. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. Pharmacol Biochem Behav. 2011;99:718–725. doi:10.1016/j.pbb.2011.06.022
   PubMed Web of Science ®Google Scholar
• Gentili M, Ronchetti S, Ricci E, et al. Selective CB2 inverse agonist JTE907 drives T cell differentiation towards a Treg cell phenotype and ameliorates inflammation in a mouse model of inflammatory bowel disease. Pharmacol Res. 2019;141:21–31. doi:10.1016/j.phrs.2018.12.005
   Web of Science ®Google Scholar
• Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000;97:9561–9566. doi:10.1073/pnas.160105897
   PubMed Web of Science ®Google Scholar
• Shapiro CM, Orlina AR, Unger P, Billings AA. Antibody response to cannabis. JAMA. 1974;230:81–82. doi:10.1001/jama.1974.03240010049030
   PubMed Web of Science ®Google Scholar
• McHugh D, Tanner C, Mechoulam R, Pertwee RG, Ross RA. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB 2. Mol Pharmacol. 2008;73:441–450. doi:10.1124/mol.107.041863
   Web of Science ®Google Scholar
• Walter L, Franklin A, Witting A, et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci. 2003;23:1398–1405. doi:10.1523/JNEUROSCI.23-04-01398.2003
   PubMed Web of Science ®Google Scholar
• Giudice ED, Rinaldi L, Passarotto M, et al. Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL-2H3 mast cells. J Leukoc Biol. 2007;81:1512–1522. doi:10.1189/jlb.1206738
   Web of Science ®Google Scholar
• Cassol OJ Jr, Comim CM, Silva BR, et al. Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture. Brain Res. 2010;1348:128–138. doi:10.1016/j.brainres.2010.06.023
   Web of Science ®Google Scholar
• El-Gohary M, Eid MA. Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum Exp Toxicol. 2004;23:149–156. doi:10.1191/0960327104ht426oa
   PubMed Web of Science ®Google Scholar
• Jan TR, Su ST, Wu HY, Liao MH. Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of splenocytes in ovalbumin-sensitized BALB/c mice. Int Immunopharmacol. 2007;7:773–780. doi:10.1016/j.intimp.2007.01.015
   PubMed Web of Science ®Google Scholar
• Dotsey E, Ushach I, Pone E, et al. Transient cannabinoid receptor 2 blockade during immunization heightens intensity and breadth of antigen-specific antibody responses in young and aged mice. Sci Rep. 2017;7. doi:10.1038/srep42584
   Web of Science ®Google Scholar
• Maresz K, Pryce G, Ponomarev ED, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med. 2007;13:492–497. doi:10.1038/nm1561
   PubMed Web of Science ®Google Scholar
• Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology. 2010;215:598–605. doi:10.1016/j.imbio.2009.04.001
   PubMed Web of Science ®Google Scholar
• Schwarz H, Blanco FJ, Lotz M. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol. 1994;55:107–115. doi:10.1016/0165-5728(94)90152-X
   PubMed Web of Science ®Google Scholar
• Chiurchiù V, Lanuti M, Catanzaro G, Fezza F, Rapino C, Maccarrone M. Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. Atherosclerosis. 2014;233:55–63. doi:10.1016/j.atherosclerosis.2013.12.042
   Web of Science ®Google Scholar
• Staiano RI, Loffredo S, Borriello F, et al. Human lung-resident macrophages express CB 1 and CB 2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. J Leukoc Biol. 2016;99:531–540. doi:10.1189/jlb.3HI1214-584R
   PubMed Web of Science ®Google Scholar
• Lee WS, Erdelyi K, Matyas C, et al. Cannabidiol limits T cell–mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation. Mol Med. 2016;22:136–146. doi:10.2119/molmed.2016.00007
   PubMed Web of Science ®Google Scholar
• Persidsky Y, Fan S, Dykstra H, Reichenbach NL, Rom S, Ramirez SH. Activation of cannabinoid type two receptors (CB2) diminish inflammatory responses in macrophages and brain endothelium. J Neuroimmune Pharmacol. 2015;10:302–308. doi:10.1007/s11481-015-9591-3
   Web of Science ®Google Scholar
• Kishimoto S, Kobayashi Y, Oka S, Gokoh M, Waku K, Sugiura T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. J Biochem. 2004;135:517–524. doi:10.1093/jb/mvh063
   PubMed Web of Science ®Google Scholar
• Roth MD, Castaneda JT, Kiertscher SM. Exposure to Δ9-tetrahydrocannabinol impairs the differentiation of human monocyte-derived dendritic cells and their capacity for T cell activation. J Neuroimmune Pharmacol. 2015;10:333–343. doi:10.1007/s11481-015-9587-z
   PubMed Web of Science ®Google Scholar
• Kapellos TS, Taylor L, Feuerborn A, et al. Cannabinoid receptor 2 deficiency exacerbates inflammation and neutrophil recruitment. FASEB J. 2019;33:6154–6167. doi:10.1096/fj.201802524R
   PubMed Web of Science ®Google Scholar
• Adhikary S, Kocieda VP, Yen JH, Tuma RF, Ganea D. Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. Blood. 2012;120:3741–3749. doi:10.1182/blood-2012-06-435362
   Web of Science ®Google Scholar
• Nam G, Jeong SK, Park BM, et al. Selective cannabinoid receptor-1 agonists regulate mast cell activation in an oxazolone-induced atopic dermatitis model. Ann Dermatol. 2016;28:22–29. doi:10.5021/ad.2016.28.1.22
   PubMed Web of Science ®Google Scholar
• Hegde VL, Singh UP, Nagarkatti PS, Nagarkatti M. Critical role of mast cells and peroxisome proliferator–activated receptor γ in the induction of myeloid-derived suppressor cells by marijuana cannabidiol in vivo. J Immunol. 2015;194:5211–5222. doi:10.4049/jimmunol.1401844
   PubMed Web of Science ®Google Scholar
• Robinson RH, Meissler JJ, Fan X, Yu D, Adler MW, Eisenstein TK. A CB2-selective cannabinoid suppresses T-cell activities and increases Tregs and IL-10. J Neuroimmune Pharmacol. 2015;10(2):318–332. doi:10.1007/s11481-015-9611-3
   Web of Science ®Google Scholar
• Stebulis JA, Johnson DR, Rossetti RG, Burstein SH, Zurier RB. Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. Life Sci. 2008;83:666–670. doi:10.1016/j.lfs.2008.09.004
   Web of Science ®Google Scholar
• Peyravian N, Deo S, Daunert S, Jimenez JJ. Cannabidiol as a novel therapeutic for immune modulation. ImmunoTargets Ther. 2020;9:131–140. doi:10.2147/ITT.S263690
   PubMed Web of Science ®Google Scholar
• Correa F, Mestre L, Docagne F, Guaza C. Activation of cannabinoid CB 2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol. 2005;145:441–448. doi:10.1038/sj.bjp.0706215
   PubMed Web of Science ®Google Scholar
• Abo-Elnazar S, Moaaz M, Ghoneim H, Molokhia T, El-Korany W. Th17/Treg imbalance in opioids and cannabinoids addiction: relationship to NF-κB activation in CD4+ T cells. Egypt J Immunol. 2014;21:33–47.
   Google Scholar
• Castillo PE, Younts TJ, Chávez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron. 2012;76:70–81. doi:10.1016/j.neuron.2012.09.020
   PubMed Web of Science ®Google Scholar
• Börner C, Smida M, Höllt V, Schraven B, Kraus J. Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. J Biol Chem. 2009;284:35450–35460. doi:10.1074/jbc.M109.006338
   PubMed Web of Science ®Google Scholar
• Katz-Talmor D, Katz I, Porat-Katz BS, Shoenfeld Y. Cannabinoids for the treatment of rheumatic diseases — where do we stand? Nat Rev Rheumatol. 2018;14:488–498. doi:10.1038/s41584-018-0025-5
   PubMed Web of Science ®Google Scholar
• Molina PE, Amedee AM, Winsauer P, Nelson S, Bagby G, Simon L. Behavioral, metabolic, and immune consequences of chronic alcohol or cannabinoids on HIV/AIDs: studies in the non-human primate SIV model. J Neuroimmune Pharmacol. 2015;10:217–232. doi:10.1007/s11481-015-9599-8
   Web of Science ®Google Scholar
• Da silva T, Hafizi S, Watts JJ, et al. In vivo imaging of translocator protein in long-term cannabis users. JAMA Psychiatry. 2019;76:1305–1313. doi:10.1001/jamapsychiatry.2019.2516
   Web of Science ®Google Scholar
• Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. 2018;17:623–639.
   PubMed Web of Science ®Google Scholar
• Śledziński P, Nowak-Terpiłowska A, Zeyland J. Cannabinoids in medicine: cancer, immunity, and microbial diseases. Int J Mol Sci. 2021;22:1–22.
   Web of Science ®Google Scholar
• Sarzi-Puttini P, Batticciotto A, Atzeni F, et al. Medical cannabis and cannabinoids in rheumatology: where are we now? Expert Rev Clin Immunol. 2019;15:1019–1032. doi:10.1080/1744666X.2019.1665997
   PubMed Web of Science ®Google Scholar
• Fitzcharles M-A, Ste-Marie PA, Clauw DJ, et al. Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints. BMC Musculoskelet Disord. 2014;15:258. doi:10.1186/1471-2474-15-258
   PubMed Web of Science ®Google Scholar
• Richardson D, Pearson RG, Kurian N, et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2008;10:R43. doi:10.1186/ar2401
   PubMed Web of Science ®Google Scholar
• Lowin T, Tingting R, Zurmahr J, Classen T, Schneider M, Pongratz G. Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts. Cell Death Dis. 2020;11:1–11. doi:10.1038/s41419-020-02892-1
   Web of Science ®Google Scholar
• Atzeni F, Nucera V, Masala IF, Sarzi-Puttini P, Bonitta G. Il-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab. Pharmacol Res. 2019;149:104402. doi:10.1016/j.phrs.2019.104402
   PubMed Web of Science ®Google Scholar
• Fonseca JE, Santos MJ, Canhão H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8:538–542. doi:10.1016/j.autrev.2009.01.012
   PubMed Web of Science ®Google Scholar
• Gui H, Liu X, Liu LR, Su DF, Dai SM. Activation of cannabinoid receptor 2 attenuates synovitis and joint distruction in collagen-induced arthritis. Immunobiology. 2015;220:817–822. doi:10.1016/j.imbio.2014.12.012
   PubMed Web of Science ®Google Scholar
• Kotschenreuther K, Waqué I, Yan S, et al. Cannabinoids drive Th17 cell differentiation in patients with rheumatic autoimmune diseases. Cell Mol Immunol. 2021;18:764–766. doi:10.1038/s41423-020-0437-4
   Web of Science ®Google Scholar
• Sarzi-Puttini P, Ablin J, Trabelsi A, Fitzcharles MA, Marotto D, Häuser W. Cannabinoids in the treatment of rheumatic diseases: pros and cons. Autoimmun Rev. 2019;18:102409. doi:10.1016/j.autrev.2019.102409
   Web of Science ®Google Scholar
• Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology. 2006;45:50–52. doi:10.1093/rheumatology/kei183
   PubMed Web of Science ®Google Scholar
• Webb M, Luo L, Ma JY, Tham CS. Genetic deletion of Fatty Acid Amide Hydrolase results in improved long-term outcome in chronic autoimmune encephalitis. Neurosci Lett. 2008;439:106–110. doi:10.1016/j.neulet.2008.04.090
   Web of Science ®Google Scholar
• Wen J, Ribeiro R, Tanaka M, Zhang Y. Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis. Neuropharmacology. 2015;99:196–209. doi:10.1016/j.neuropharm.2015.07.010
   Web of Science ®Google Scholar
• De Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernández-Ruiz J. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology. 2012;62:2299–2308. doi:10.1016/j.neuropharm.2012.01.030
   Web of Science ®Google Scholar
• Paolicelli D, Direnzo V, Manni A, et al. Long-term data of efficacy, safety, and tolerability in a real-life setting of THC/CBD oromucosal spray-treated multiple sclerosis patients. J Clin Pharmacol. 2016;56:845–851. doi:10.1002/jcph.670
   PubMed Web of Science ®Google Scholar
• Celius EG, Vila C. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity. Brain Behav. 2018;8(5):e00962. doi:10.1002/brb3.962
   PubMed Web of Science ®Google Scholar
• Zettl UK, Rommer P, Hipp P, Patejdl R. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord. 2016;9:9–30. doi:10.1177/1756285615612659
   PubMed Web of Science ®Google Scholar
• Baker D, Jackson SJ, Pryce G. Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol. 2007;152:649–654. doi:10.1038/sj.bjp.0707458
   PubMed Web of Science ®Google Scholar
• Pesce M, D’Alessandro A, Borrelli O, et al. Endocannabinoid-related compounds in gastrointestinal diseases. J Cell Mol Med. 2018;22:706–715. doi:10.1111/jcmm.13359
   PubMed Web of Science ®Google Scholar
• Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis. 2009;15:1678–1685. doi:10.1002/ibd.20960
   PubMed Web of Science ®Google Scholar
• Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004;113:1202–1209. doi:10.1172/JCI200419465
   PubMed Web of Science ®Google Scholar
• D’Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J. 2006;20:568–570. doi:10.1096/fj.05-4943fje
   PubMed Web of Science ®Google Scholar
• Sałaga M, Mokrowiecka A, Zakrzewski PK, et al. Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). J Crohns Colitis. 2014;8:998–1009. doi:10.1016/j.crohns.2014.01.025
   PubMed Web of Science ®Google Scholar
• Alhouayek M, Lambert DM, Delzenne NM, Cani PD, Muccioli GG. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J. 2011;25:2711–2721. doi:10.1096/fj.10-176602
   PubMed Web of Science ®Google Scholar
• Engel MA, Kellermann CA, Burnat G, Hahn EG, Rau T, Konturek PC. Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid [TNBS]-induced colitis. J Physiol Pharmacol. 2010;61:89–97.
   PubMed Web of Science ®Google Scholar
• Marquéz L, Suárez J, Iglesias M, Bermudez-Silva FJ, Rodríguez de Fonseca F, Andreu M. Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One. 2009;4:e6893. doi:10.1371/journal.pone.0006893
   PubMed Web of Science ®Google Scholar
• Duncan M, Mouihate A, Mackie K, et al. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol. 2008;295:G78–G87. doi:10.1152/ajpgi.90285.2008
   Web of Science ®Google Scholar
• Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O’Sullivan SE. Palmitoylethanolamide and cannabidiol prevent inflammation-induced hyperpermeability of the human gut in vitro and in vivo-a Randomized, Placebo-controlled, Double-blind Controlled Trial. Inflamm Bowel Dis. 2019;25:1006–1018. doi:10.1093/ibd/izz017
   Web of Science ®Google Scholar
• Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:891–896. doi:10.1097/MEG.0b013e328349bb4c
   PubMed Web of Science ®Google Scholar
• Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20:472–480. doi:10.1097/01.MIB.0000440982.79036.d6
   PubMed Web of Science ®Google Scholar
• Allegretti JR, Courtwright A, Lucci M, Korzenik JR, Levine J. Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2809–2814. doi:10.1097/01.MIB.0000435851.94391.37
   PubMed Web of Science ®Google Scholar
• Mbachi C, Attar B, Oyenubi O, et al. Association between cannabis use and complications related to ulcerative colitis in hospitalized patients: a propensity matched retrospective cohort study. Med (United States). 2019;98. doi:10.1097/MD.0000000000016551
   Google Scholar
• Benson MJ, Abelev SV, Connor SJ, et al. Medicinal cannabis for inflammatory bowel disease: a survey of perspectives, experiences, and current use in Australian patients. Crohns Colitis. 2020;2:1–15.
   Google Scholar
• Naftali T, Lev LB, Yablekovitz D, Half E, Konikoff FM. Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J. 2011;13:455–458.
   PubMed Web of Science ®Google Scholar
• Naftali T, Mechulam R, Marii A, et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn’s disease, a Randomized Controlled Trial. Dig Dis Sci. 2017;62:1615–1620. doi:10.1007/s10620-017-4540-z
   PubMed Web of Science ®Google Scholar
• Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11(10):1276–1280.e1. doi:10.1016/j.cgh.2013.04.034
   PubMed Web of Science ®Google Scholar
• Irving PM, Iqbal T, Nwokolo C, et al. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. Inflamm Bowel Dis. 2018;24:714–724. doi:10.1093/ibd/izy002
   PubMed Web of Science ®Google Scholar
• Naftali T, Bar-Lev Schleider L, Sklerovsky Benjaminov F, Lish I, Konikoff FM, Ringel Y. Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects. Eur J Gastroenterol Hepatol. 2019;31:1376–1381. doi:10.1097/MEG.0000000000001565
   PubMed Web of Science ®Google Scholar
• Giorgi V, Bongiovanni S, Atzeni F, Marotto D, Salaffi F, Sarzi-Puttini P. Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. Clin Exp Rheumatol. 2020;38:53–59.
   PubMed Web of Science ®Google Scholar
• Katz D, Katz I, Porat-Katz BS, Shoenfeld Y. Medical cannabis: another piece in the mosaic of autoimmunity? Clin Pharmacol Ther. 2017;101:230–238. doi:10.1002/cpt.568
   PubMed Web of Science ®Google Scholar